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ABSTRACT
Background We can improve healthcare services by 
better understanding current provision. One way to 
understand this is by linking data sets from clinical and 
national audits, national registries and other National 
Health Service (NHS) encounter data. However, getting to 
the point of having linked national data sets is challenging.
Objective We describe our experience of the data 
application and linkage process for our study ‘LAUNCHES 
QI’, and the time, processes and resource requirements 
involved. To help others planning similar projects, 
we highlight challenges encountered and advice for 
applications in the current system as well as suggestions 
for system improvements.
Findings The study set up for LAUNCHES QI began in 
March 2018, and the process through to data acquisition 
took 2.5 years. Several challenges were encountered, 
including the amount of information required (often 
duplicate information in different formats across 
applications), lack of clarity on processes, resource 
constraints that limit an audit’s capacity to fulfil requests 
and the unexpected amount of time required from the 
study team. It is incredibly difficult to estimate the 
resources needed ahead of time, and yet necessary to do 
so as early on as funding applications. Early decisions can 
have a significant impact during latter stages and be hard 
to change, yet it is difficult to get specific information at 
the beginning of the process.
Conclusions The current system is incredibly complex, 
arduous and slow, stifling innovation and delaying 
scientific progress. NHS data can inform and improve 
health services and we believe there is an ethical 
responsibility to use it to do so. Streamlining the number 
of applications required for accessing data for health 
services research and providing clarity to data controllers 
could facilitate the maintenance of stringent governance, 
while accelerating scientific studies and progress, leading 
to swifter application of findings and improvements in 
healthcare.
THE OPPORTUNITY
In the UK, challenges exist for many lifelong 
conditions such as congenital heart disease 
(CHD),1 cancer,2 renal disease,3 haemophilia4 
and cystic fibrosis.5 The UK has a wealth of 
high- quality registry and audit data.
We can improve healthcare services by 
better understanding current provision and 
outcomes6 through linking data sets from 
clinical and national audits, registries and 
other National Health Service (NHS) activity 
data. In our research study, LAUNCHES QI 
(box 1), we are using five linked national data 
sets to generate important understanding 
about services for CHD.
THE PROBLEM
Linking five national data sets has been chal-
lenging, laborious and at times demoralising 
and seemingly hopeless. Coordinating appli-
cations to multiple data controllers and navi-
gating the terminology, legal and governance 
Strengths and limitations of this study
 ► Provide valuable advice and insight to those em-
barking on research requiring linked national data 
sets, reassurance to those currently negotiating the 
system and suggest improvements throughout the 
data application ecosystem for the future.
 ► Our experiences will overlap with those of prospec-
tive patient recruiting studies and clinical trials.
 ► This is a single study using linked retrospective au-
dit data, applicability of experiences and advice may 
vary according to the readers requirements.
 ► Clinical trials and studies recruiting participants will 
have a greater document burden than described 
here, but may also have found that the system was 
more applicable to their research than for retrospec-
tive data analysis.
 ► The data sets applied for covered English centres 
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structures can feel overwhelming. The process is time- 
consuming, complex and iterative.
Although we are a single study, much of the LAUNCHES 
process will be applicable to other studies, although 
with variations in university/institutional requirements, 
research ethics committee (REC) requirements, the 
legal basis through General Data Protection Regula-
tion (GDPR) compliance and the common law duty of 
confidentiality, and data controller specific requirements 
(figure 1).
OUR INTENTION
We hope to help others applying for and linking registry, 
health administration and audit data sets by describing 
the processes, duration, resource requirements and 
challenges involved in LAUNCHES and offering some 
advice and suggestions for system improvements based 
on our experience. We hope this paper will contribute 
to a renewed national conversation about balancing 
justifiably stringent requirements of data protection and 
governance with the potential opportunity for beneficial 
research capitalising on the wealth of healthcare data 
available.7–13
CHALLENGES AND LEARNING
Volume of information required
Table 1 details the full set of documents for the data 
application processes (47 in total comprising 384 pages), 
which were required by 11 controllers or departments and 
submitted 162 times in total. Although similar study infor-
mation was requested for each of the seven application 
forms and the protocol, each required different wording, 
structure and detail. Several documents, designed for 
clinical trials and other prospective studies recruiting 
participants, were difficult to adapt to our study context.
Requests for alterations and further information prior 
to approval were received between one and nine times 
for each data controller. Additional communications 
followed, for data preparation and transfer (figure 2).
Following approvals, further follow- up on the study 
document set was required. Examples are requesting 
publication of privacy notices on partner websites, submit-
ting amendments, annual reports to ethics and the Confi-
dentiality Advisory Group (CAG) and annual renewals for 
each data sharing agreement.
Person time required
It was tricky to assess in advance the person time required. 
Once the extent of the workload became clearer, we 
increased our 20% full- time equivalent (FTE) study 
coordinator to 40% FTE for the beginning part of the 
study, but at the cost of less study coordinator support 
towards the end of the study (fortunately our funder was 
supportive). In retrospect the time required from the 
principal investigators to check, edit and input into the 
documentation was underestimated.
The teams working at the national audits also had 
limited resources and on occasions important day- to- day 
work necessarily took priority over processing data 
requests.
Costs
Allocating accurate funds for access to data sets is chal-
lenging. (1) It is difficult to anticipate the final costs for 
Box 1 Description of the LAUNCHES QI study and its data 
application process
LAUNCHES QI: Linking AUdit and National data sets in 
Congenital HEart Services for Quality Improvement
The aim of LAUNCHES is to improve services for congenital heart dis-
ease and provide a template for other lifelong conditions by linking five 
national data sets to: describe patient trajectories through secondary 
and tertiary care; identify useful metrics for driving quality improvement 
(QI) and informing commissioning and policy; explore variation across 
services to identify priorities for QI.
Data application process
Planning the linkage process began with preparing the funding applica-
tion. At that stage we liaised with each of the audits and developed an 
initial plan for linkage, including timelines and costs. This necessarily 
involved some guess work and we ended up underestimating both the 
time and costs involved.
The data application process in earnest (see figure 1) began in March 
2018, with the start of the funding. The core data set was the National 
Congenital Heart Disease Audit (NCHDA) data set including cases from 
April 2000 to March 2017. Patients within NCHDA were matched to re-
cords in the Paediatric Intensive Care Audit Network (PICANet), Intensive 
Care National Audit and Research Centre- Case Mix Programme 
(ICNARC- CMP), Hospital Episode Statistics (HES) and Office for National 
Statistics (ONS) mortality data. Resulting in a linked data set allowing 
the analysis of longitudinal patient trajectories through the healthcare 
system. The data controller for NCHDA and PICANet is the Health Quality 
Improvement Partnership, for ICNARC- CMP is ICNARC and for HES and 
ONS is NHS Digital.
Our initial linkage plan was to use NHS Digital to act as a ‘trusted third 
party’, recommended as a standard approach to data linkage. However, 
following one of the author’s experience and discussions with audit part-
ners about risks of delay and feasibility, we opted for a method where 
each data controller linked their own data to the NCHDA identifiers.
Before beginning the process we met with colleagues attempting a sim-
ilar study and were able to draw on their experience and use their draft 
forms, and our study coordinator had prior experience applying to NHS 
Digital, so we consider that we had a head start that potentially reduced 
the time taken to receive approvals. We had allowed 6 months to com-
plete this process, and expected to have the linked five data sets ready 
for analysis shortly after this.
Required first were university approvals for: data protection, insurance, 
information governance and approval of the completed Integrated 
Research Application System application, protocol and other study 
documents. This information and approvals made up the document 
set (table 1) to submit to the Research Ethics Committee (required as 
LAUNCHES involved patients identified in the context of their past use of 
services in the National Health Service), and the Confidentiality Advisory 
Group to apply for section 251 approval to link and process the data 
(as it is not feasible to contact patients from the audits for retrospec-
tive individual consent). While these applications were under review, we 
could begin the four data applications for the five data sets, to submit 
for approval to the three data controllers.
 on S
eptem









pen: first published as 10.1136/bm





3Taylor JA, et al. BMJ Open 2021;11:e047575. doi:10.1136/bmjopen-2020-047575
Open access
some data sets and they were underestimated in the grant 
application. (2) Although you apply for data for the full 
length of the project, you are required to extend the data 
sharing agreement annually, this required additional 
funds for charges, study coordination time and principal 
investigator (PI) time. (3) In the case of NHS Digital, 
requesting even one additional field after approval could 
result in a charge equal to that of the original data extract.
Process delays
A timeline of the process is given in figure 2. Study 
permissions, including university processes and receiving 
ethical and CAG approval, took 8 months, and the data 
applications took between 3 and 7 months. Acquiring the 
data took a further 7–10 months.
Below we give examples of factors that caused delay and 
confusion to illustrate how seemingly small decisions had 
significant consequence and sometimes the complexity 
was overwhelming.
One small decision…
Small, seemingly inconsequential, decisions in filling 
out forms had far reaching consequences which did not 
become apparent until much later. In our case, a small 
decision in the Integrated Research Application System 
(IRAS) filter questions, made early to avoid redoing 
weeks of initial work on the IRAS form, ultimately ended 
up creating a lot of extra work. The resulting additional 
forms and required approvals are still being processed 
with an NHS site 2 years on.
Lack of clarity
We applied for two data sets (National Congenital 
Heart Disease Audit and Paediatric Intensive Care Audit 
Network) that had the same data controller (Health 
Quality Improvement Partnership (HQIP)), so we were 
unsure whether one or two applications were required. 
We were initially told one (which we prepared) but later 
told that two were needed. Therefore, two forms were 
submitted to the same data controller, to be discussed 
at the same meeting, with virtually identical content but 
slightly tailored to each specific data set.
Requiring inside knowledge
Not all fields were listed in data dictionaries, and some 
derived fields that we asked for (eg, age at an event instead 
of date) needed negotiation with each data provider. We 
were lucky to have project partners from each audit who 
knew that derived fields were possible.
Bureaucracy
Each time that we recruited research staff, some of the 
data sharing agreements required updating. Even such a 
minor change took up to 6 weeks and needed to be done 
separately for each data agreement, delaying when new 
staff could begin working with the data.
Being too specific
For IRAS and CAG we stated that we would be requesting 
life status and age at last known life status from Office for 
National Statistics (ONS), but our advisory group subse-
quently suggested also requesting type of residence at 
death and hospital name. This change created a cascade 
of amendments resulting in significant delay. Had we 
stated that we would be applying for ONS data but not 
specified the fields, the amendment process would not 
have been necessary.
Not being specific enough
It was difficult to know how specific to be. As the data 
application developed, some changes to the fields 
were required and making these changes was a lengthy 
process. In our case, a failure to specify the number of 
decimal places required for age and our intention to 
request month and year of birth in our CAG applica-
tion, coupled with a misunderstanding following asking 
Figure 1 Flow diagram of the study approval and data application process. The right hand orange figure provides the detail 
in the orange section (data application box) on the left blue hand figure. CAG, Confidentiality Advisory Group; HES, Hospital 
Episode Statistics; HQIP, Health Quality Improvement Partnership; HRA, Health Research Authority; ICNARC CMP, Intensive 
Care National Audit and Research Centre Case Mix Programme; IRAS, Integrated Research Application System; NCHDA, 
National Congenital Heart Disease Audit; NHS, National Health Service; ONS, Office for National Statistics; PICANet, Paediatric 
Intensive Care Audit Network; REC, research ethics committee; UCL, University College London.
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for date of event in one data set caused problems when 
it came to data extraction. This required a CAG amend-
ment to resolve.
The impact of infrequent data controller meetings
In addition to the time spent preparing applications, 
timing applications to coincide with monthly (or some-
times less frequent) data controller approval meetings was 
difficult, and not all controllers provide information on 
meeting dates. Narrowly missing a meeting meant waiting 
a month or more for the next meeting, and if there were 
requests for further information then the process was 
delayed by another month. Additionally, an amendment 
for one data controller required changes to all other data 
applications, which lengthened the process considerably. 
We had five different approval bodies across the data sets.
Maintaining enthusiasm among project partners
One impact from process delays was the challenge of 
keeping project partners engaged and enthusiastic. The 
timeline our partners had originally agreed to had to be 
extended twice, with few interim developments to report 
back.
The fear of legal misstep, delaying data sharing
Failure to comply with the data protection principles 
could mean a fine of up to €20 million, or 4% of an 
organisation’s total worldwide annual turnover, which-
ever is higher.14 Data controllers with good processes in 
place but without complete clarity on remit potentially 
contribute to delays because of concerns about a possible 
breach. For example, one data controller repeatedly 
asked us to clarify that our collaborators were advisory 
only, without access to the linked data set, despite us 
providing that assurance at each stage.
Acquiring data
Once all approvals are in place, the process to gain 
access to and link the data are also lengthy. For example, 
following approval from the data controller (HQIP), 
it took 7 months for the cohort to then be constructed 
and matching data sent to the other data providers for 
linkage.
Acquisition following approvals was delayed by a combi-
nation of: limited staff resources in National Institute 
for Cardiovascular Outcomes Research for initiating 
linkage with other audits, amendments to obtain specific 
data fields, CAG amendments and an amendment for 
a bespoke linkage plan (that was later shelved because 
of lack of data controller capacity). While some of these 
delays could have been avoided in hindsight, it is almost 
impossible to anticipate everything ahead of time, and 
the process for any changes is often as lengthy as a fresh 
application.
Reusing the data
Having completed the data linkage, funding was 
received for another study that would use the same 
data set. For most of the data sets, entirely new appli-
cations were required to use the existing data for this 
new but similar purpose, and despite our previous expe-
rience in LAUNCHES, it has taken another 2 years to 
complete the process, with the NHS Digital application 
still pending.
Figure 2 Timeline of the permission process, order and time taken in LAUNCHES QI, from first submission to data acquisition. 
Each box represents the time from submission of the data application to transfer of the data to UCL, for each data set. Note 
that not all requests for further information and responses have been included! *Processes as at UCL. CAG, Confidentiality 
Advisory Group; HRA, Health Research Authority; ICNARC, Intensive Care National Audit and Research Centre; NHS, National 
Health Service; NICOR, National Institute for Cardiovascular Outcomes Research; PICANet, Paediatric Intensive Care Audit 
Network; REC, Research Ethics Committee; UCL, University College London.
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USEFUL ADVICE
Love thy research assistants/study coordinators (the legal 
amount)
These are roles that often get squeezed at application 
stage to reduce costs and can be challenging to resource 
if part- time. But these roles are absolutely crucial in 
accessing data.
Find people who have been there before you
Researchers who were further ahead in their data applica-
tion journey shared their learning and expertise with us. 
This helped speed up the initial process of preparing the 
applications.
Have a flexible start up period
Having an initial data application period in the project 
with just the PIs and a study coordinator funded allowed 
us to react early to delays and quickly adjust the timeline.
Add clinical and audit experts to the team
Input from clinicians on data fields helped with data 
minimisation versus research realisation (particularly a 
problem for exploratory work). We also found it useful 
to include, where possible, collaborators working for data 
controllers and audits.
Plan your data minimisation and beware of differences in how 
some terms are interpreted
You will need to describe how you have minimised the 
need for patient identifiers, and all fields requested will 
require justification. In doing so be sure to correctly state 
if data will be de- identified, pseudonymised or further 
anonymised. Some consider anonymised data to be 




It has taken us over 2.5 years to create our linked data set, 
so most of our analyses and outputs on what was originally 
a 2- year project are yet to be completed. But things could 
have been worse: we have an understanding funder and 
an incredible study coordinator, and we experienced no 
project staff turnover or major changes in audit staff.
There is no centralised or easily accessible support for 
how to navigate the system—each new project team is on 
its own. So how might the system improve? Below are our 
suggestions, which are also summarised in figure 3.
A shorter, streamlined system for retrospective data
Ethics and CAG
The forms for ethical and CAG approval are set up for 
clinical trials and cohorts prospectively recruiting partic-
ipants. A shorter application form specific to routinely 
collected retrospective data would be helpful. CAG 
have now introduced what is known as the precedent 
set pathway15 to enable a more timely review process, 
which although a step in the right direction applies 
only to specific situations, known as the ‘precedent set 
Figure 3 Illustrates the suggested system improvements for the future. The coloured bubbles contain the suggestions, with 
each larger bubble representing the authority that should consider these changes. CAG, Confidentiality Advisory Group.
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categories’. These categories include: applications to 
identify a cohort of patients and subsequently seek their 
consent; accessing data on site to extract anonymised 
data; validity of consent; data cleansing of historical 
studies; time limited access to undertake record linkage/
validation and anonymisation of data.
The latter category was not a feasible category for us 
to apply for expedited review as we required pseudony-
mised data from each data controller to link all data sets 
at University College London. The original data linkage 
plan had involved each audit sending their data to NHS 
Digital, so we would receive the final linked data set 
only. However, following feedback from a study that had 
adopted this strategy, that this had lengthened the process, 
without them having access to any of the data sets during 
this time, we opted for each audit completing their own 
linkage to the core NCHDA dataset. This allowed us to 
receive and begin working on each data set as it reached 
us, without needing to have received every data set. NHS 
Digital was the lengthiest application process and there-
fore the original planned linkage would have delayed us 
even further. We did not seek to receive the identifiers 
from each audit for the sake of data minimisation and 
governance.
Single application
A template form with the same questions for all 
healthcare- related data controllers would reduce work-
load significantly. Each data controller would receive the 
same form, with the specification of all fields requested 
from each data set.
Defined remit
The various application forms ask several questions 
regarding patient benefit (eg, anticipated magnitude of 
patient benefit, how it will be achieved and measured, 
what contribution universities make to improving patient 
services, number of planned manuscripts), that are reit-
erated from funding, REC and CAG, but not consistently 
required in all data applications.
These questions were sometimes additional to the 
actual data application forms and so introduced delays 
as emails were sent back and forth (see figure 2). A joint 
system between funders, REC/CAG and data controllers 
so that each could be sure that important questions on 
feasibility, importance and process have been answered 
while minimising burden on applicants (and committees 
within each organisation) would be beneficial. In the 
absence of such a system, clarity on remit would reduce 
the pressure on the data controllers with the more conser-
vative approaches to obtain such detailed information, 
and in some cases prevent duplication of review of ethics, 
CAG applications, amendments and annual reports. For 
context, some applications required details of research 
outputs and benefits. The amendment to use the same 
data for another study (see ‘reusing data’) resulted in the 
re- review of the initial application with further questions 
on this already approved section. The questions referred 
to whether some benefits listed would actually be consid-
ered outputs. Defining remit could consider the level of 
detail necessary for each part of the process.
Funders
Funders are increasingly acknowledging the time it will 
take to access and link data, and the uncertainties around 
timing. Additionally, they need to ensure that projects 
requiring external data have been resourced appropri-
ately with sufficient budget for data access and project 
management. A more ambitious response could be 
centralised project coordinators within funding bodies 
that are assigned to successful projects to help manage 
data access. This may be more efficient as the funders 
would build up expertise and experience of data access 
processes and make it easier to resource part- time project 
coordination.
Data controllers/processors; REC and CAG
Staff at the point of contact (on both sides) are bearing the 
brunt of the frustrated emails and the fraying patience of 
applicants working to their deadlines. Audits are working 
hard, encompassing much more than providing data to 
researchers, with their own staffing and resource issues 
and have to abide by stringent data governance rules. The 
underlying systems seem to be the problem, but there are 
few opportunities for feedback.
Available guidance needs streamlining as it is currently 
lengthy, spread across a number of web pages and often 
hard to follow or ambiguous. Some independent organ-
isations have attempted to provide guidance to help 
navigate the system. For example, the Medical Research 
Council have developed an online tool to help determine 
the approvals needed,16 and HQIP have just funded and 
published short films and written resources on under-
standing health data access designed to improve acces-
sible, introductory information about the rules and 
processes governing access to health data.17
Another possibility being adopted in other countries18 19 
is a central authority for processing and approving appli-
cations, and implementing linkage, thereby reducing the 
number of data controllers carrying out effectively the 
same review, and increasing efficiency. However, some 
countries adopting such systems have reported that such 
systems are not without delays and problems and that 
further improvements are required.19–21
Universities
Research assistants/study coordinators are really 
important for the success of this kind of research and play 
vital roles in information governance and data security, 
yet they are often funded on rolling temporary contracts 
with no job security or progression, often resulting in the 
loss of valuable expertise and experience. Universities 
should consider how to protect these roles, for example, 
they could support permanent, centralised study coor-
dinators who could assist several projects across the 
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university. Similar problems of job security also affect the 
data processors.
We also experienced an increase in the requirements 
of the research and development (‘R&D’) departments 
of the universities and the NHS sites, with little if any flex-
ibility to take study type into account.
Tackling fear and confusion over data protection
How GDPR and other data protection laws apply to these 
sorts of retrospective studies is hard to understand and 
open to different interpretations. The importance of data 
governance and potential penalties for breaching GDPR 
mean that often the most conservative interpretation is 
used which often increases the complexity and workload. 
Clearer guidance, a single form and clarification on remit 
would alleviate this, as would guidance on the inclusion 
of collaborators and processes to share data after a data 
set is established.
 
LESSONS FROM THE PANDEMIC
During 2020, research governance was relaxed in pursuit 
of rapid scientific evidence into COVID-19 aetiology, risk 
factors and treatments. This included a fast track review 
for ethics review,22 the pause of the need for approval 
under Regulation 3 (4) of the Health Service Control of 
Patient Information Regulations 200223 and the release 
of data and change in process by some data controllers.24 
This expedited progress of all studies into COVID-19, and 
prioritisation of COVID-19 research, shows that there is 
room to simplify the process.10 This provides an important 
opportunity to learn from what happened during the 
COVID-19 pandemic, and what could be adapted for the 
future.
Strengths and limitations
Our experience of an ambitious project to link five data 
sets may not be entirely generalisable to other researchers, 
especially those applying for fully anonymised data from 
an established research database.
However for most studies, although some differences 
would apply for ethics and CAG requirements, such 
requirements will still need to be considered at the outset 
of the study. Data sets required will differ for different 
projects, but we expect that each research team will 
encounter similar governance requirements although 
with different requirements of the relevant data control-
lers. Longitudinal studies and clinical trials may have 
many approvals in place, but may be still experiencing 
their own challenges with changing governance require-
ments that could delay renewal of permissions.
Our challenges were not unique,7 11 13 25 and align with 
other recommendations that have been suggested.8 10 13 26 27 
The publication of our experience is an important addi-
tion to the research method dissemination, hopefully 
facilitating the development of new and more efficient 
data access systems.
Conclusions
The current system is incredibly complex, arduous and 
slow, stifling innovation and delaying scientific progress. 
NHS data can inform and improve health services and 
we believe there is an ethical responsibility to use it to do 
so.12
Streamlining the number of applications required for 
accessing data for health services research and providing 
clarity to data controllers will facilitate the maintenance 
of stringent governance, while accelerating scientific 
studies and progress, leading to swifter application of 
findings and improvements in healthcare.
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